Nuveen
AVBP icon

Nuveen’s ArriVent BioPharma AVBP Stock Holding History

Nuveen’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75M Buy
107,851
+51,012
+90% +$1.51M ﹤0.01% 2259
2026
Q1 		$1.31M Buy
56,839
+3,221
+6% +$72.7K ﹤0.01% 2460
2025
Q4 		$1.08M Buy
53,618
+5,955
+12% +$124K ﹤0.01% 2581
2025
Q3 		$879K Hold
47,663
– – ﹤0.01% 2682
2025
Q2 		$1.04M Buy
47,663
+3,381
+8% +$70.2K ﹤0.01% 2585
2025
Q1 		$819K Hold
44,282
– – ﹤0.01% 2723
2024
Q4 		$1.18M Hold
44,282
– – ﹤0.01% 2641
2024
Q3 		$1.04M Buy
44,282
+26,712
+152% +$606K ﹤0.01% 2742
2024
Q2 		$326K Buy
17,570
+4,638
+36% +$82.7K ﹤0.01% 3129
2024
Q1 		$231K Buy
+12,932
New +$261K ﹤0.01% 3153

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's AVBP Position: Q2 2026 in Review

Nuveen increased its ArriVent BioPharma (AVBP) stake by 90% in Q2 2026, buying an estimated $1.51M and bringing the position to 107,851 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2259.

Nuveen first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Nuveen held 107,851 shares of ArriVent BioPharma worth $3.75M as of Q2 2026.
  • Nuveen bought 51,012 ArriVent BioPharma shares in Q2 2026, an estimated $1.51M.
  • ArriVent BioPharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2259 holding.
  • Nuveen first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.